Share
Justin Thacker
Crystalys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on addressing the significant unmet medical needs of people living with gout, has appointed Justin Thacker as Chief Financial Officer (CFO).
His addition to the executive leadership team supports Crystalys’ continued progress, including the advancement of Phase 3 clinical trials for dotinurad.
Mr. Thacker brings more than 25 years of financial leadership experience, including over two decades in the life sciences industry across both private and public companies at clinical and commercial stages. He has played a central role in multiple initial public offerings, strategic financings, product launches, and mergers and acquisitions, providing financial leadership through periods of rapid growth and organizational transformation.
Most recently, Mr. Thacker served as CFO of Capstan Therapeutics, where he helped guide the company through significant expansion and its acquisition by AbbVie for up to US$2.1 billion. Prior to that, he was CFO at Aristea Therapeutics, where he led core finance functions and IPO readiness initiatives. His previous experience also includes senior finance leadership roles at Design Therapeutics, Synthorx (acquired by Sanofi), ACADIA Pharmaceuticals, Auspex Pharmaceuticals (acquired by Teva Pharmaceuticals), and Cadence Pharmaceuticals (acquired by Mallinckrodt).
Mr. Thacker began his career at PricewaterhouseCoopers LLP and holds a Master of Accountancy and a Bachelor of Science in Accounting and General Management from Kansas State University. He is a Certified Public Accountant in the State of Missouri.
His appointment further strengthens Crystalys Therapeutics’ leadership team as the company advances its clinical programs and works toward delivering meaningful treatment options for patients with gout.
